Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
To read all of these articles and more, visit centerforbiosimilars.com.
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
India has a strong pharma network, with more than 10,000 manufacturing facilities, over 3,000 pharma companies.
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Inventions made in a particular country are generally first-filed in that country before entering the United States via a direct Paris ...
In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback